Market News AIOpen the app

GPCR stock news · Structure Therapeutics

Stories about Structure Therapeutics (GPCR) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for GPCR

Follow Structure Therapeutics (GPCR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GPCR
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 6:07 PM ET · Opinion

    Morgan Stanley has cut its price target for Structure Therapeutics from $126 to $117 but still rates it as 'Outperform.

    Neutral

    Morgan Stanley cut its price target for Structure Therapeutics to $117 from $126 but kept its Outperform rating. The mixed analyst view does not change the company's outlook.